Rx Reimbursement Model Must Change For Pharma To Flourish, Castellani Says
Executive Summary
The pharmaceutical industry must work to change two "insidious" reimbursement paradigms if it hopes to be able to continue to develop additional medications, PhRMA CEO John Castellani said in his first major policy address.
You may also be interested in...
Can Jersey City Be A Cure For What Ails Pharma?
One of the highlights of the Pharmaceutical Research & Manufacturers of America's annual meeting in Jersey City, N.J., was a fill-in-the-blank exercise.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.